CARY, N.C., September 25, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Servier as a limited specialty pharmacy provider for VORANIGO (vorasidenib) for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma oroligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.
VORANIGO, approved by the U.S. Food and Drug Administration (FDA) on August 6, 2024, is the first targeted drug developed specifically for people with Grade 2 IDH-mutant gliomas and is a significant advancement in the field of brain cancer treatment. The positive results from the clinical trial indicate that VORANIGO could slow tumor progression and delay the need for more aggressive treatments.
“This development represents a significant step forward in the treatment of brain cancer and positive outcomes for patients,” said George Paschal, senior director of Business Development for Biologics by McKesson. “It brings hope for improved quality of life for those affected by this type of brain cancer. Biologics by McKesson is proud to collaborate with Servier to serve as a specialty pharmacy provider to provide this potentially life-changing treatment.”
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For more information about the symptoms, diagnosis, and treatment of patients with IDH-mutant diffuse glioma click here. For more information about VORANIGO, including full prescribing information, click here.
###
About Biologics by McKesson
Biologics by McKesson is an independent specialty pharmacy with more than 30 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers, and biopharma, so together, they can deliver better care and outcomes for every patient.
About McKesson Oncology and Specialty Solutions
It’s an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care.
- McKesson is fueling discovery by helping patients participate in cutting-edge trials closer to home through its joint venture with Sarah Cannon Research Institute.
- The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers.
- Ontada®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care.
- As a leading distributor of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them.
- And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines.